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Background: The unique expression pattern and immunogenic properties of cancer/testis antigens make them
ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen is frequently expressed in non-small
cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown
promising results. However, little is known about the expression of other cancer/testis antigens in NSCLC. In the
present study the expression of cancer/testis antigens GAGE, NY-ESO-1 and SP17 was investigated in patients with
completely resected, early stage, primary NSCLC.
Methods: Tumor biopsies from normal lung tissue and from a large cohort (n = 169) of NSCLC patients were
examined for GAGE, NY-ESO-1 and SP17 protein expression by immunohistochemical analysis. The expression of
these antigens was further matched to clinical and pathological features using univariate cox regression analysis.
Results: GAGE and NY-ESO-1 cancer/testis antigens were not expressed in normal lung tissue, while SP17 was
expressed in ciliated lung epithelia. The frequency of GAGE, NY-ESO-1 and SP17 expression in NSCLC tumors
were 26.0% (44/169), 11.8% (20/169) and 4.7% (8/169), respectively, and 33.1% (56/169) of the tumors expressed at
least one of these antigens. In general, the expression of GAGE, NY-ESO-1 and SP17 was not significantly associated
with a specific histotype (adenocarcinoma vs. squamous cell carcinoma), but high-level GAGE expression (>50%)
was more frequent in squamous cell carcinoma (p = 0.02). Furthermore, the frequency of GAGE expression was
demonstrated to be significantly higher in stage II-IIIa than stage I NSCLC (17.0% vs. 35.8%; p = 0.02). Analysis of the
relation between tumor expression of GAGE and NY-ESO-1 and survival endpoints revealed no significant associations.
Conclusion: Our study demonstrates that GAGE, NY-ESO-1 and SP17 cancer/testis antigens are candidate targets for
immunotherapy of NSCLC and further suggest that multi-antigen vaccines may be beneficial.
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Harnessing the power of our immune system has long
been a promising approach to treating cancer, and a large
number of tumor antigens that might be used as targets
for immunotherapy have been identified. Cancer/testis
(CT) antigens are among the most promising due to their
highly restricted expression to immune privileged cells of
the testis and placenta in normal tissues as well as their
natural immunogenic properties [1,2]. Current strategies* Correspondence: mgjerstorff@health.sdu.dk
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reproduction in any medium, provided the oremploying CT antigens as targets for immunotherapy
include vaccination [1,3] and adoptive transfer of T
cells with genetically-modified T cell receptors [4-6].
Non-small cell lung cancer (NSCLC) accounts for more
than 85% of new cases of lung cancer, which is the leading
cause of cancer deaths worldwide [7], highlighting the
need for novel therapeutic strategies for treatment of this
disease. Cellular and humoral immune responses to CT
antigens have been reported in NSCLC patients [8-14],
suggesting that these proteins may be candidate targets
for cancer immunotherapy of NSCLC. In addition, CT
antigen sero-reactivity may be of diagnostic value for
NSCLC patients [15]. Interestingly, adjuvant therapyal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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MAGE-A3-positive NSCLC has shown promising results
[16], and allogeneic lymphocytes expressing recombinant
T-cell receptors recognizing CT antigens NY-ESO-1 and
MAGE-A3 were recently shown to effectively kill lung
cancer cells [4]. This suggests that cancer immunotherapy
targeting CT antigens may be an effective treatment for
NSCLC. However, characterization of additional targets
in NSCLC is needed to further develop broadly applicable,
effective and specific immunotherapy regimens.
An important factor to consider when selecting appro-
priate targets for cancer immunotherapy is the expression
frequency within the cancer of interest. In this study,
we report a systematic analysis of the expression of the
CT antigens GAGE, NY-ESO-1 and SP17 in early-stage
NSCLC. NY-ESO-1 and the GAGE multi-gene family
are members of the chromosome X-encoded CT antigens,
which generally exhibit complete testis-specificity and are
expressed at the spermatogonial stage of spermatogenesis
[2]. In contrast, autosomal encoded CT antigens, such as
SP17, are characterized by low expression in a limited
number of non-testis, normal, tissues and tend to be
expressed in the late stages of spermatogenesis. Our results
will enhance the selection of appropriate targets for
immunotherapeutic treatment of this disease.
Methods
Tumor samples
NSCLC surgical resection specimens were collected
as diagnostic specimens from patients treated at the
University Hospital of Odense from 1992–1999. The
experiment was conducted in compliance with the Helsinki
declaration and was approved by the ethical committee
of Funen and Vejle County (VF20050069). Informed
consent from participants was not needed for this type
of experiment. All patients had undergone complete
surgical resection without further treatment (neoadjuvant
or adjuvant chemo- or radiotherapy). The histological
subtypes of the tumors were established by morphology
using light microscopy or by TTF1 and p63 status using
immunohistochemistry. Formalin-fixed and paraffin-em-
bedded tumor sections were stained with hematoxylin and
eosin, and two 1 mm cores were punched from the central
part of the tumors were transferred to tissue microarrays
for further analysis.
Immunohistochemical staining
Methods for immunohistochemical staining of GAGE,
NY-ESO-1 and SP17 in formalin-fixed, paraffin-embedded
tissues and the characteristics of the antibodies used have
been described previously [17-19]. Notably, the anti-GAGE
antibody likely recognizes all members of the GAGE
family. In brief, tissue sections were cut, deparaffinized,
treated with 1.5% H202 in Tris-buffered saline (pH 7.5)for 10 min to block endogenous peroxidase activity,
rinsed in distilled H2O, demasked for antigen retrieval
and washed in TNT buffer (0.1 M Tris, 0.15 M NaCl,
0.05% Tween-20, pH 7.5). Primary monoclonal antibodies
(anti-GAGE (clone M3) [18], 1:100; anti-NY-ESO-1 (clone
E978) [18] 1:25; anti-SP17 (clone 22) [17] 1:400) were
diluted in antibody diluent (DAKO Cytomation, Glostrup,
Denmark) and added to sections for 1 h at room
temperature. Sections were washed with TNT and
incubated with horseradish peroxidase-conjugated Envision
or Powervision polymer (DAKO Cytomation) for 30 min,
followed by another wash with TNT. The final reaction
product was visualized by incubating with 3,3’-diamino-
benzidine (DAB) + substrate-chromogen for 10 min,
followed by washing with H2O and counterstaining of
sections with Mayers hematoxylin before mounting in
AquaTex (Merck Inc., Whitehouse Station, NJ, USA).
Histological evaluation
Immunohistochemical staining was evaluated for percent-
age of positive tumor cells by a skilled pathologist. Since
positively-stained cells were generally strongly stained,
differences in intensity was not assessed. The specimens
were scored in four categories: 0 (≤ 1%), 1 (>1% - ≤ 10%),
2 (>10% - ≤ 50%) and 3 (>50%). Cells were considered
positive if staining was convincingly observed in either the
cytoplasm or the nuclei, or both, regardless of intensity.
The cores were reported as missing if none or few tumor
cells were present (<30 cells).
Statistical analysis
Univariate regression analysis using Cox proportional-
hazard models and Kaplan-Meier survival analysis was
performed using STATA software. The comparison of
CT antigen expression with histotype and clinical stage
was analyzed with the two-sided chi-squared test using
a 5% significance level. Analysis of CT antigen co-expres-
sion was done with the Z test comparing expected and
observed proportions of positive tumors.
Results and discussion
We evaluated the expression of GAGE, NY-ESO-1 and
SP17 CT antigens in normal lung tissue (n = 5) and tumors
from 169 patients with completely resected, early stage
primary NSCLC. Patient characteristics are presented
in Table 1. GAGE, NY-ESO-1 and SP17 expression was
examined using well-characterized antibodies and pre-
viously established methods for immunohistochemical
staining [17,18]. GAGE and NY-ESO-1 was not detected
in normal lung tissues, but SP17 was expressed in a subset
of ciliated epithelial cells of the bronchi (Figure 1), in
accordance with previously published data [17,18]. As
shown in Table 2, GAGE proteins were detected in 26.0%
(44/169) of NSCLC tumors and in 63.6% (28/44) of the
Table 1 Characteristics of patients included in the study
Pathological parameter Cases %
Gender Male 104 62.1
Female 65 37.9
Histology Adenocarcinoma 81 47.9
Squamous cell carcinoma 84 49.7
NOS* 4 2.4
TNM stage IA 31 18.3
IB 57 33.7
IIA 40 23.7
IIB 17 10.1
IIIA 24 14.2
*NOS ‘Not otherwise specified’. Negative for adenocarcinoma marker TFF1 and
squamous cell carcinoma marker p63.
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cells. This demonstrates that the expression frequency of
GAGE proteins in NSCLC is similar to that of MAGE-A3,
which is currently being tested as a vaccine target in
NSCLC [16,20], as mentioned above. All GAGE-positive
tumor cells exhibited cytoplasmic staining, but there
were clear differences in the level of nuclear staining
among and within tumors, ranging from absent to intense
(Figure 1). This subcellular distribution is in agreementFigure 1 Immunohistochemical analysis of GAGE, NY-ESO-1 and SP17
staining with monoclonal antibodies recognizing GAGE, NY-ESO-1 and SP1
lung and testis were included as controls. Magnification: ×20 (lung and teswith a previous report on GAGE protein expression in a
small set of lung cancers and other types of cancer [18].
NY-ESO-1 was detected in 11.8% (20/169) of tumors and,
as with GAGE, the distribution in most tumors was near
homogenous (>50% positive tumor cells in 14 of 20 tumors
examined) (Table 2). This expression frequency is in
line with previous studies reporting 8.3-25% NY-ESO-
1-positive NSCLC tumors [20-23]. The discrepancy in
reported frequencies of NY-ESO-1 expression may be
due to multiple parameters such as variation in clinical
material (sampling, stage, subtype, treatment), staining
protocol, scoring system/personnel etc. It is possible
that the present study, using two 1 mm cores per tumor,
may have included more false negatives than studies using
whole tumor sections. However, NY-ESO-1 was relatively
homogenously expressed in the majority of NSCLC
tumors analyzed, supporting the validity of the two-core
approach. The subcellular localization of NY-ESO-1 in
NSCLC tumors was predominantly cytoplasmic. SP17
was detected in 4.7% (8/169) NSCLC tumors, which is
comparable to existing targets of NSCLC (e.g. EML4-ALK)
[24,25]. In all 8 positive tumors, less than 10% of the tumor
cells were positive. Notably, the SP17-positive tumor cells
exhibited a scattered distribution within tumors in contrast
to GAGE and NY-ESO-1, which were most often eitherexpression in clinical NSCLC specimens. Representative tumor
7. Percentages of positive cells within tumors are indicated. Normal
tis) and ×40 (tumors).
Table 2 Expression of GAGE, NY-ESO-1 and SP17 in human NSCLC
Tumor expression
of antigen
Histotype All NSCLC specimens
(n = 169)Adenocarcinoma (n = 81) Squamous cell carcinoma (n = 88)* p-value
GAGE 15 (18.5%) 29 (33.0%) 0.19 44 (26.0%)
>1% - ≤ 10% 5 (6.2%) 5 (5.7%)
>10% - ≤ 50% 2 (2.5%) 4 (4.6%)
>50% 8 (9.9%) 20 (22.7%) 0.02
NY-ESO-1 8 (9.9%) 12 (13.6%) 0.49 20 (11.8%)
>1% - ≤ 10% 2 (2,5%) 1 (1.1%)
>10% - ≤ 50% 2 (2.5%) 1 (1.1%)
>50% 4 (4.9%) 10 (11.4%) 0.13
SP17 4 (4.9%) 4 (4.6%) 0.76 8 (4.7%)
>1% - ≤ 10% 4 (4.9%) 4 (4.6%)
>10% - ≤ 50% 0 0
>50% 0 0
* The survival of the four NOS patients resembled that of patients with squamous cell carcinoma and were therefore included in this group for statistical analysis.
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been proposed as markers of cancer stem cells [26], and
further studies should be conducted to uncover the identity
of this small subset of SP17-positive tumor cells. It is
also notable that while the frequency of tumors positive
for both GAGE and NY-ESO-1 proteins suggested a degree
of coordinated expression of these proteins (p = 0.03),
neither showed any tendency to co-expression with SP17
(p = 0.65 and p = 1.00) (Figure 2). Unlike GAGE and
NY-ESO-1, SP17 is expressed in ciliated normal tissues
in addition to testis, indicating that the encoding genes
exhibit differences in tissue-specific regulation, which may
explain the significant expression dissimilarities observed
in NSCLC and other cancers [17]. It further confirms
the notion that chromosome X encoded and autosomal
encoded CT antigens exhibit different expression profiles
in normal and malignant tissues.Figure 2 Venn diagram demonstrating overlap between GAGE,
NY-ESO-1 and SP17 expression in NSCLC specimens. Numbers
represent positive tumors among the total of 169 NSCLC specimens
included in the analysis.The panel of NSCLC included both adenocarcinomas
and squamous cell carcinomas. In general, the expression
of GAGE, NY-ESO-1 and SP17 CT antigens were not
associated with any specific histology type (Table 2), but
strongly GAGE-positive tumors (>50% positive tumor
cells) were more frequent in squamous cell carcinomas
(p = 0.02). A similar correlation has been reported between
MAGE-A3 and MAGE-A4 and squamous cell carcinoma
[20]. Adenocarcinomas and squamous cell carcinomas
have been shown to differ in their DNA methylation
patterns [27,28], and since promoter hypomethylation
is important inducer of CT antigen gene expression in
cancer cells [2], this may explain the differences in CT
antigen expression between these two subtypes of NSCLC.
GAGE protein expression significantly correlated with
disease progression (p = 0.02), i.e. 17.0% (15/88) of stage
I and 35.8% (29/81) of stage II-IIIa tumors were GAGE-
positive (Table 3). NY-ESO-1 expression also tended to
associate with advanced disease stages, but not to a
statistically significant degree. Similarly, the frequency of
MAGE-A4-positive tumors has been reported to be a
significantly higher in stage II-IV than stage I NSCLC [20].
The association between CT antigen expression and
disease-specific and overall survival was also analyzed
for GAGE and NY-ESO-1 (Figure 3); SP-17-positive
specimen numbers were too low to allow for a statistical
analysis. Although GAGE expression tended to correlate
with poor survival, neither GAGE nor NY-ESO-1 was
significantly associated with disease-specific or overall
survival.
Our results show that the CT antigens GAGE, NY-ESO-
1 and SP17 are expressed in a considerable proportion of
NSCLC and may therefore serve as candidate targets
for immunotherapeutic treatments of this disease. Fur-
thermore, GAGE and NY-ESO-1 were present in more
Table 3 Expression of GAGE, NY-ESO-1 and SP17 in
different stages of NSCLC
Antigen TNM stage
Ia-b (n = 88) II-IIIa (n = 81) p-value
GAGE 15 (17.0%) 29 (35.8%) 0.02
>1% - ≤ 10% 4 (4.5%) 6 (7.4%)
>10% - ≤ 50% 0 6 (7.4%)
>50% 11 (12.5%) 17 (21.0%)
NY-ESO-1 9 (10.2%) 11 (13.6%) 0.36
>1% - ≤ 10% 0 3 (3.7%)
>10% - ≤ 50% 2 (2.3%) 1 (1.2%)
>50% 7 (7.9%) 7 (8.7%)
SP17 4 (4.5%) 4 (4.9%) 0.94
>1% - ≤ 10% 4 (4.5%) 4 (4.9%)
>10% - ≤ 50% 0 0
>50% 0 0
Figure 3 Kaplan-Meier plots evaluating disease-specific and overall su
expression, are shown. Log-rank test was used.
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(14/20) of the positive cases, respectively. It seems
likely that treatment directed against a tumor antigen
broadly expressed within tumors may be most effective,
although this has not been demonstrated. The relative
homogeneity of GAGE and NY-ESO-1 in NSCLC tumors
further strengthens their therapeutic potential, while the
scattered expression of SP17 in NSCLC tumors suggests
that this is a relatively poor target for NSCLC. Our results
demonstrate significant differences in tumor expression
of the two chromosome X-encoded CT antigens GAGE,
NY-ESO-1 and the autosomal CT antigen SP17 in NSCLC.
While only one tumor was positive for all three CT
antigens, 56/169 (33.1%) were positive for at least one of
these CT antigens, demonstrating that immunotherapeutic
strategies should aim at different CT antigen targets,
including both chromosome X-encoded and autosomal
encoded antigens.
Conclusions
This study determines the expression frequency and
correlation with clinical parameters of GAGE, NY-ESO-1
and SP17 CT antigens in NSCLC, which may facilitatervival of NSCLC patients, according to GAGE and NY-ESO-1
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immunotherapy of NSCLC.
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